Patients:
10 patients were considered in this study. Patients included in the study were candidate for allogeneic hematopoietic stem cell transplantation with a donor with DNAM-1 above 8 ng / ml. Five patients were in the MSC pulse HSC injection group and five patients in no MSC group. A total of 5 men and 5 women were enrolled. The mean age of the patients in the MSC recipient group was 27.8 + 8.49 and in the non-recipient group was 36 + 12.76. The MSC recipient group consisted of 2 males and 3 females and the non-MSC recipient group consisted of 3 males and 2 females. All patients underwent BU/FU Myeloablative chemotherapy regimen including busulfan 0.8 mg/kg every 6 hours for 4 days and fludarabine 30 mg/m2 of body surface (IV) for 5 days. Cyclosporine and methotrexate were considered as a prophylaxis regimen for patients with GvHD. CysA was administered to patients at a dose of 3 mg/kg/day a day before transplantation (day -1). The duration of prophylactic effect of cyclosporine was 6 months and in the absence of symptoms in 3 months, the dose was reduced. The initial dose of MTX was +10 mg / m2 on day +1 and then +6 mg / m2 on days +3, +6 and +11. Mesenchymal stem cells were injected into the MSC recipient group 1 hour before the injection of hematopoietic stem cell transplantation and 24 h after transplantation. The dose of BM-MSC for injection was 1-2×106 cell/kg (Table 1,2).